Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment

  • Yoo, Su-Jin (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Lee, Jeong-Eun (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Jung, Sun-Young (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Park, Dong-Il (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Park, Myoung-Rin (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Park, Hee-Sun (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Jung, Sung-Soo (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Kim, Ju-Ock (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine) ;
  • Kim, Sun-Young (Department of Internal Medicine, Chungnam National University Hospital & Cancer Research Institute, Chungnam National University School of Medicine)
  • Received : 2011.09.02
  • Accepted : 2011.09.27
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths. Most patients were presented with advanced disease at the time of diagnosis. In advanced NSCLC, it is almost impossible to anticipate complete remission by using only cytotoxic chemotherapy or molecularly targeted agents. In our case, two patients were diagnosed as advanced NSCLC and received chemotherapy. They achieved complete response (CR). After finishing treatment, disease recurred. They were retreated with the same regimens and achieved second CR. Until now, they have received each regimen, continuously, and the CR state has been maintained.

Keywords

References

  1. DeVita VT, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
  2. Lee SY, Park JY. Personalized therapy in lung cancer: focused on molecular targeted therapy. J Lung Cancer 2011;10:1-12. https://doi.org/10.6058/jlc.2011.10.1.1
  3. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
  4. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7:
  5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: small cell lung cancer, v.3. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
  6. Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 2001;12:23-7.

Cited by

  1. Drug rechallenge and treatment beyond progression-implications for drug resistance vol.10, pp.10, 2012, https://doi.org/10.1038/nrclinonc.2013.158
  2. Rechallenge Strategy in Cancer Therapy vol.98, pp.10, 2012, https://doi.org/10.1159/000507816